Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion
Portfolio Pulse from
Portnoy Law Firm is representing Intellia Therapeutics investors in a class action lawsuit alleging misleading statements about the company's NTLA-3001 drug development. The lawsuit claims Intellia made false representations about the viability of their viral-based editing program and ultimately discontinued the NTLA-3001 program, causing a 15% stock price drop on January 9, 2025.
April 11, 2025 | 8:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Class action lawsuit alleges misleading statements about NTLA-3001 drug development, potentially impacting investor confidence and company valuation.
The lawsuit directly targets Intellia Therapeutics, alleging false statements about NTLA-3001's development. The 15% stock price drop and program discontinuation suggest significant negative market perception.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100